# Ohtuvayre® (ensifentrine) helped improve lung function in Chinese adult patients in in data published in peer reviewed journal.

*biotech · news · 2026-04-20 · The Manila Times*

## Key points

- Phase 3 ENHANCE-CHINA trial showed Ohtuvayre significantly improved lung function in Chinese COPD patients.
- Ohtuvayre is the first COPD therapy in China with a novel mechanism of action in over 10 years.
- Nuance Pharma's New Drug Application for Ohtuvayre was accepted for review by China's NMPA in January 2026.
- Merck/MSD now holds exclusive Ohtuvayre rights outside of Greater China after acquiring Verona Pharma.

**Companies:** Merck & Co., Inc., Nuance Pharma, Verona Pharma
**Countries:** China, Hong Kong, Macau, United States

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/04/20/tmt-newswire/pr-newswire/nuance-pharma-announces-publication-of-phase-3-enhance-china-data-in-the-chest-journal/2323580)

---

Canonical: https://newsio.io/n/a7d80c37-939b-46d4-96c0-ffe33aa69e0e/ohtuvayre-ensifentrine-helped-improve-lung-function-in-chinese-adult-patients-in
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works